Lucentis market seen reaching $4.87 million by 2030
The Business Research Company says the global Lucentis (ranibizumab) market will grow from $3.74 million in 2025 to $3.96 million in 2026, then reach $4.87 million by 2030. The report points to rising retinal disease rates, higher healthcare spending and growing demand for anti-VEGF treatments as the main drivers.
Why it matters: - Lucentis remains a key treatment for retinal diseases that can cause vision loss. - The market outlook points to continued demand as eye disorders become more common and access to care improves. - The report highlights pressure from biosimilar competitors, which could reshape pricing and adoption.
What happened: - The Business Research Company published its Lucentis (Ranibizumab) Global Market Report 2026, covering market size, trends and forecasts through 2035. - The report estimates the Lucentis market at $3.74 million in 2025 and $3.96 million in 2026. - The company projects the market will reach $4.87 million by 2030. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.
The details: - Lucentis is a prescription drug used for eye conditions tied to abnormal blood vessel growth in the retina. - The drug is a recombinant monoclonal antibody fragment that blocks vascular endothelial growth factor, or VEGF. - Blocking VEGF helps reduce retinal swelling and damage in age-related macular degeneration and diabetic macular edema. - Recent growth has been supported by clinical outcomes in macular degeneration, more diabetic retinopathy cases, an aging population, greater ophthalmologist adoption and regulatory approvals. - Future growth is expected to come from higher retinal disease prevalence, better access to eye care, biosimilar competition, more awareness of early diagnosis and drug delivery advances. - The report identifies sustained reliance on anti-VEGF therapies, broader use in retinal vascular disorders, preference for intravitreal injections, growth in specialized ophthalmology clinics and a stronger focus on preserving vision as key trends. - The report says rising eye disorder prevalence is driven by aging populations, genetic risks, smoking, poor diet, extended screen time and sunlight exposure. - The National Eye Institute forecasts around 2.2 million Americans will be blind by 2030. - Higher healthcare spending is another driver because it supports reimbursement, coverage and distribution for treatments like Lucentis. - UK healthcare spending rose 5.6% from 2022 to 2023 to about $317.63 billion, according to the Office for National Statistics. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The Business Research Company says the 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrices, Excel dashboards, market hotspot infographics and updated graphics and tables. - Download a free sample of the report. - View the full Lucentis market report.
Between the lines: - The forecast suggests the Lucentis market is growing, but not explosively, which makes competitive pressure from biosimilars more important. - The emphasis on eye-care access and early diagnosis suggests much of the next phase of growth depends on healthcare system capacity, not just drug demand. - The regional split points to a mature North American market and more expansion headroom in Asia-Pacific.
What's next: - The market is expected to keep growing through 2030 if retinal disease rates and treatment access continue to rise. - Competitive dynamics will likely depend on how biosimilars affect prescribing patterns and pricing. - The report signals more use of analytics tools and regional segmentation in future market tracking.
The bottom line: - Lucentis is a steady-growth ophthalmology market shaped by aging populations, retinal disease prevalence and expanding eye-care access, with biosimilar competition emerging as the main watchpoint.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Asia Pacific News Today
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.